SIGNIFICANCE OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 GENE (SERPINE1: 5G>4G) POLYMORPHISM IN CHORIONIC DETACHMENT AND PLACENTAL ABRUPTION IN EARLY PREGNANCY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To estimate the significance of allelic variants of SERPINE1 (PAI-1) gene polymorphism in chorionic detachment and placental abruption in early pregnancy. Subjects and methods. A study group consisted of 67 women with recurrent miscarriage in early pregnancy. A control group included 53 healthy primigravidas. SERPINE1: 5G>4G gene polymorphism was determined using the method of adjacent probes with commercial test systems (OOO «NPO DNK-Tekhnologiya», Russia). Ultrasound study was made employing a 512-channel digital scanner (Siemens SonoLine Elegra, Germany). Results. The average detection time for retrochorial and retroamniotic hematomas was 8.3±0.4 and 12.1±0.5 weeks, respectively. Premature detachment of the chorion and placenta was shown to be associated with the number of 4G alleles of the SERPINE1 (PAI-1) gene in the genotype of a patient. In the 4G/4G genotype, the detachments are 1.5 times more common than those in the 5G/4G genotype. The use of selective antifibrinolytics in combination with antiaggregants and/or low-molecular-weight heparins improves pregnancy outcomes. Conclusion. The 4G allele of the SERPINE1 (PAI-1) gene polymorphism is associated with the development of chorionic and placental detachments in early pregnancy. Moreover, in the 4G/4G genotype, the detachments are 1.5 times more frequently encountered than those in the 5G/4G genotype.

Full Text

Restricted Access

About the authors

P. A KIRYUSHCHENKOV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: masha-kirmail@mail.ru

Z. S KHODZHAYEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: zhodjaeva@mail.ru

N. K TETRUASHVILI

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: tetruly@mail.ru

A. E DONNIKOV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: donnikov@mdl-lab.ru

D. M BELOUSOV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: slides@narod.ru

E. V ANDAMOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: elena_doctor@mail.ru

M. A TAMBOVTSEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: tambovtsevamr@mail.ru

References

  1. Герштейн Е.С., Кушлинский Н.Е., Лякина Л.Т. и др. Активаторы плазминогена урокиназного и тканевого типов и их ингибитор (PAI-I) в цитозольной фракции при заболеваниях щитовидной железы // Вестн. РАМН. — 2001. — С. 32—33.
  2. Кирющенков П.А., Белоусов Д.М., Александрина О.С. Патогенетическое обоснование тактики ведения отслойки хориона и плаценты на ранних сроках беременности // Гинекология. — 2010. — Т. 12, № 1. — С. 36—39.
  3. Сидельникова В.М., Сухих Г.Т. Невынашивание беременности. — М.: МИА, 2010. — С. 31—43; 380—413.
  4. Тромбогеморрагические осложнения в акушерско-гинекологической практике / Под ред. А.Д. Макацария. — М.: МИА, 2011. — С. 53—57; 635— 656.
  5. Feng Q., Liu Y., Liu K. et al. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation // Placenta. — 2000. — Vol. 21. — P. 184—193.
  6. Iribarren J.L., Jimenez J.J., Hernandez D. et al. Postoperative bleeding in cardiac surgery: the role of tranexamic acid in patients homozygous for the 5G polymorphism of the plasminogen activator inhibitor-1 gene // Anesthesiology. — 2008. — Vol. 108, N 4. — P. 596—602.
  7. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease // N. Engl. J. Med. — 2000. — Vol. 342, № 24. — P. 1792—1801.
  8. Ma Z., Paek D., Oh C.K. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation // Clin. Exp. Allergy. — 2009. — Vol. 39, № 8. — P. 1136—1144.
  9. Panahloo A., Mohamed-Ali V., Lane A. et al. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene // Diabetes. — 1995. — Vol. 44, № 1. — P. 37—42.
  10. Wiklund P.G., Nilsson L., Ardnor S.N. et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts // Stroke. — 2005. — Vol. 36, № 8. — P. 1661—1665.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies